Besides, it remains unclear whether differences in clinical course between limited (stage I and II) and advanced-stage DLBCL should be attributed to early disease detection or to distinct biologic features, including the prognostic impact of a MYC-R [12]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.